daunorubicin has been researched along with eicosapentaenoic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bay, JO; Béné, MC; Bertrand, P; Bonmati, C; Carré, M; Darrouzain, F; Gallego-Hernanz, MP; Gyan, E; Hérault, O; Hunault, M; Lioure, B; Peterlin, P; Picou, F; Pigneux, A; Récher, C; Ternant, D; Vallet, N | 1 |
2 other study(ies) available for daunorubicin and eicosapentaenoic acid
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Docosahexaenoic Acids; Eicosapentaenoic Acid; Emulsions; Feasibility Studies; Fish Oils; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; NF-E2-Related Factor 2 | 2022 |